Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study
Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn's disease (CD) failing anti- Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described. Aims and...
| Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de documento: | artigo |
| Estado: | Versão publicada |
| Data de publicação: | 2021 |
| País: | España |
| Recursos: | Universidad de Barcelona |
| Repositório: | Dipòsit Digital de la UB |
| OAI Identifier: | oai:diposit.ub.edu:2445/179326 |
| Acesso em linha: | https://hdl.handle.net/2445/179326 |
| Access Level: | Acceso aberto |
| Palavra-chave: | Malaltia de Crohn Malalties inflamatòries intestinals Inflammatory bowel diseases Crohn&apos s disease |
| id |
ES_3e42f3f86c64e78bccd97f6ff8fae6c3 |
|---|---|
| oai_identifier_str |
oai:diposit.ub.edu:2445/179326 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort StudyAlbshesh, AhmadTaylor, JoshuaSavarino, Edoardo V.Truyens, MarieArmuzzi, AlessandroRibaldone, Davide G.Shitrit, Ariella Bar-GilFibelman, MorineMolander, PauliinaLiefferinckx, ClaireNancey, StephaneKorani, MohamedRutka, MariannBarreiro de Acosta, ManuelDomislovic, ViktorSurís, GerardEriksson, CarlAlves, CatarinaMpitouli, AfroditiDi Jiang, CarolineTepeš, KatjaColetta, MarinaFoteinogiannopoulou, KalliopiGisbert, Javier P.Amir-Barak, HadarAttauabi, MohamedSeidelin, JakobAfif, WaqqasMarinelli, CarlaLobatón, TrianaPugliese, DanielaMaharshak, NitsanCremer, AnnelineLimdi, Jimmy K.Molnár, TamásOtero Alvarin, BorjaKrznaric, ZeljkoMagro, FernandoKarmiris, KonstantinosRaine, TimDrobne, DavidKoutroubakis, IoannisChaparro, MariaYanai, HenitBurisch, JohanKopylov, UriMalaltia de CrohnMalalties inflamatòries intestinalsInflammatory bowel diseasesCrohn&aposs diseaseBackground: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn's disease (CD) failing anti- Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described. Aims and methods: In this retrospective multicenter cohort study, we aimed to investigate the effectiveness of VDZ and UST as a third-class biologic in patients with CD. Results: Two-hundred and four patients were included; 156/204 (76%) patients received VDZ as a second- and UST as a third-class therapy (group A); the remaining 48/204 (24%) patients received UST as a second- and VDZ as a third-class therapy (group B). At week 16-22, 87/156 (55.5%) patients and 27/48 (56.2%) in groups A and B, respectively, responded to treatment (p = 0.9); 41/156 (26.2%) and 15/48 (31.2%) were in clinical remission (p = 0.5). At week 52; 89/103 (86%) patients and 25/29 (86.2%) of the patients with available data had responded to third-class treatment in groups A and B, respectively (p = 0.9); 31/103 (30%) and 47/29 (24.1%) were in clinical remission (p = 0.5). Conclusion: Third-class biological therapy was effective in more than half of the patients with CD. No differences in effectiveness were detected between the use of VDZ and UST as a third-class agent.MDPI AG2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/179326Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.3390/jcm10132914Journal of Clinical Medicine, 2021, vol. 10, num. 13, p. 2914https://doi.org/10.3390/jcm10132914cc by (c) Albshesh, Ahmad et al., 2021http://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1793262026-05-27T06:46:51Z |
| dc.title.none.fl_str_mv |
Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study |
| title |
Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study |
| spellingShingle |
Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study Albshesh, Ahmad Malaltia de Crohn Malalties inflamatòries intestinals Inflammatory bowel diseases Crohn&apos s disease |
| title_short |
Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study |
| title_full |
Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study |
| title_fullStr |
Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study |
| title_full_unstemmed |
Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study |
| title_sort |
Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study |
| dc.creator.none.fl_str_mv |
Albshesh, Ahmad Taylor, Joshua Savarino, Edoardo V. Truyens, Marie Armuzzi, Alessandro Ribaldone, Davide G. Shitrit, Ariella Bar-Gil Fibelman, Morine Molander, Pauliina Liefferinckx, Claire Nancey, Stephane Korani, Mohamed Rutka, Mariann Barreiro de Acosta, Manuel Domislovic, Viktor Surís, Gerard Eriksson, Carl Alves, Catarina Mpitouli, Afroditi Di Jiang, Caroline Tepeš, Katja Coletta, Marina Foteinogiannopoulou, Kalliopi Gisbert, Javier P. Amir-Barak, Hadar Attauabi, Mohamed Seidelin, Jakob Afif, Waqqas Marinelli, Carla Lobatón, Triana Pugliese, Daniela Maharshak, Nitsan Cremer, Anneline Limdi, Jimmy K. Molnár, Tamás Otero Alvarin, Borja Krznaric, Zeljko Magro, Fernando Karmiris, Konstantinos Raine, Tim Drobne, David Koutroubakis, Ioannis Chaparro, Maria Yanai, Henit Burisch, Johan Kopylov, Uri |
| author |
Albshesh, Ahmad |
| author_facet |
Albshesh, Ahmad Taylor, Joshua Savarino, Edoardo V. Truyens, Marie Armuzzi, Alessandro Ribaldone, Davide G. Shitrit, Ariella Bar-Gil Fibelman, Morine Molander, Pauliina Liefferinckx, Claire Nancey, Stephane Korani, Mohamed Rutka, Mariann Barreiro de Acosta, Manuel Domislovic, Viktor Surís, Gerard Eriksson, Carl Alves, Catarina Mpitouli, Afroditi Di Jiang, Caroline Tepeš, Katja Coletta, Marina Foteinogiannopoulou, Kalliopi Gisbert, Javier P. Amir-Barak, Hadar Attauabi, Mohamed Seidelin, Jakob Afif, Waqqas Marinelli, Carla Lobatón, Triana Pugliese, Daniela Maharshak, Nitsan Cremer, Anneline Limdi, Jimmy K. Molnár, Tamás Otero Alvarin, Borja Krznaric, Zeljko Magro, Fernando Karmiris, Konstantinos Raine, Tim Drobne, David Koutroubakis, Ioannis Chaparro, Maria Yanai, Henit Burisch, Johan Kopylov, Uri |
| author_role |
author |
| author2 |
Taylor, Joshua Savarino, Edoardo V. Truyens, Marie Armuzzi, Alessandro Ribaldone, Davide G. Shitrit, Ariella Bar-Gil Fibelman, Morine Molander, Pauliina Liefferinckx, Claire Nancey, Stephane Korani, Mohamed Rutka, Mariann Barreiro de Acosta, Manuel Domislovic, Viktor Surís, Gerard Eriksson, Carl Alves, Catarina Mpitouli, Afroditi Di Jiang, Caroline Tepeš, Katja Coletta, Marina Foteinogiannopoulou, Kalliopi Gisbert, Javier P. Amir-Barak, Hadar Attauabi, Mohamed Seidelin, Jakob Afif, Waqqas Marinelli, Carla Lobatón, Triana Pugliese, Daniela Maharshak, Nitsan Cremer, Anneline Limdi, Jimmy K. Molnár, Tamás Otero Alvarin, Borja Krznaric, Zeljko Magro, Fernando Karmiris, Konstantinos Raine, Tim Drobne, David Koutroubakis, Ioannis Chaparro, Maria Yanai, Henit Burisch, Johan Kopylov, Uri |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
Malaltia de Crohn Malalties inflamatòries intestinals Inflammatory bowel diseases Crohn&apos s disease |
| topic |
Malaltia de Crohn Malalties inflamatòries intestinals Inflammatory bowel diseases Crohn&apos s disease |
| description |
Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn's disease (CD) failing anti- Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described. Aims and methods: In this retrospective multicenter cohort study, we aimed to investigate the effectiveness of VDZ and UST as a third-class biologic in patients with CD. Results: Two-hundred and four patients were included; 156/204 (76%) patients received VDZ as a second- and UST as a third-class therapy (group A); the remaining 48/204 (24%) patients received UST as a second- and VDZ as a third-class therapy (group B). At week 16-22, 87/156 (55.5%) patients and 27/48 (56.2%) in groups A and B, respectively, responded to treatment (p = 0.9); 41/156 (26.2%) and 15/48 (31.2%) were in clinical remission (p = 0.5). At week 52; 89/103 (86%) patients and 25/29 (86.2%) of the patients with available data had responded to third-class treatment in groups A and B, respectively (p = 0.9); 31/103 (30%) and 47/29 (24.1%) were in clinical remission (p = 0.5). Conclusion: Third-class biological therapy was effective in more than half of the patients with CD. No differences in effectiveness were detected between the use of VDZ and UST as a third-class agent. |
| publishDate |
2021 |
| dc.date.none.fl_str_mv |
2021 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
https://hdl.handle.net/2445/179326 |
| url |
https://hdl.handle.net/2445/179326 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.relation.none.fl_str_mv |
Reproducció del document publicat a: https://doi.org/10.3390/jcm10132914 Journal of Clinical Medicine, 2021, vol. 10, num. 13, p. 2914 https://doi.org/10.3390/jcm10132914 |
| dc.rights.none.fl_str_mv |
cc by (c) Albshesh, Ahmad et al., 2021 http://creativecommons.org/licenses/by/3.0/es/ info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
cc by (c) Albshesh, Ahmad et al., 2021 http://creativecommons.org/licenses/by/3.0/es/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
MDPI AG |
| publisher.none.fl_str_mv |
MDPI AG |
| dc.source.none.fl_str_mv |
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) reponame:Dipòsit Digital de la UB instname:Universidad de Barcelona |
| instname_str |
Universidad de Barcelona |
| reponame_str |
Dipòsit Digital de la UB |
| collection |
Dipòsit Digital de la UB |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869406521294585856 |
| score |
15,301603 |